Status:
COMPLETED
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Neoplasms
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The purpose of this clinical study is to establish the maximum tolerated dose of BMS-754807 when administered orally on a once daily schedule in subjects with solid tumors.
Eligibility Criteria
Inclusion
- Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group performance 0-1
Exclusion
- Any disorder with dysregulation of glucose homeostasis
- Dumping syndrome
- History of glucose intolerance
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00898716
Start Date
September 1 2009
End Date
July 1 2011
Last Update
November 30 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Chuo-Ku, Tokyo, Japan, 104-0045